2435.T

The company's capital structure and liquidity position are not fully assessable due to the lack of balance-sheet inputs and no going-concern language in the source documents. However, the shares outstanding for both basic and diluted are the same at 11,221,963, indicating no immediate dilution risk.

Profitability and returns are not directly quantifiable from the provided data, but the last actual EPS is reported at 31.00 JPY, and the last actual revenue is 17,829,000,000 JPY. These figures suggest a potentially profitable operation, though a direct comparison to industry medians is not possible without further data.

Segment and geographic exposure details are not provided in the available data, so the revenue concentration and geographic distribution cannot be assessed. The company's operations are likely concentrated in its core biotechnology and healthcare services, but specific segment contributions are not disclosed.

The growth trajectory is not explicitly outlined in the data, but the last actual revenue of 17,829,000,000 JPY provides a baseline for future performance. Without additional historical revenue data or outlook projections, the company's growth potential remains speculative.

Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and the absence of going-concern language in the source documents. The dilution risk is currently low, as the basic and diluted shares outstanding are equal, indicating no recent or expected dilution.

Recent events and filings are not detailed in the provided data, so no specific recent developments can be cited. The company's financial and operational status is primarily based on the last actual EPS and revenue figures.